Insitro

San Francisco, United States Founded: 2018 • Age: 8 yrs
An AI-enabled platform is developed for infectious disease treatment.
Request Access

About Insitro

Insitro is a company based in San Francisco (United States) founded in 2018.. Insitro has raised $643.21 million across 3 funding rounds from investors including Verily, ARE and WuXi AppTec. The company has 257 employees as of December 31, 2023. Insitro has completed 1 acquisition, including Haystack Sciences. Insitro offers products and services including insitro Platform and Therapeutic Pipeline. Insitro operates in a competitive market with competitors including BridgeBio, Spark Therapeutics, Alnylam, ATAI and Ultragenyx, among others.

  • Headquarter San Francisco, United States
  • Employees 257 as on 31 Dec, 2023
  • Sectors
    Healthcare
  • Phone
    *********
  • Website
    *********
  • Social
    *********
Operational Areas
Healthcare → Biotechnology, Genomics & Life Sciences Research
Healthcare → Biotechnology, Genomics & Life Sciences Research
Key Metrics
  • Annual Revenue
  • Net Profit
  • EBITDA
  • Total Equity Funding
    $643.21 M (USD)

    in 3 rounds

  • Latest Funding Round
    $400 M (USD), Series C

    Mar 15, 2021

  • Investors
    Verily

    & 16 more

  • Employee Count
    257

    as on Dec 31, 2023

  • Investments & Acquisitions
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Products & Services of Insitro

Insitro offers a comprehensive portfolio of products and services, including insitro Platform and Therapeutic Pipeline. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.

Primary

Integrates data to accelerate drug discovery and development processes

Focuses on metabolism, oncology, and neuroscience for new medicines

People of Insitro
Headcount 50-200
Employee Profiles 20
Board Members and Advisors 8
Employee Profiles
People
Stephen Meadows
Associate Director, Administration | Executive Assistant To The CEO
People
Sungjin Lee
Director
People
Ajamete Kaykas
Chief eXploration Officer & Head of Neuroscience
People
Eva-Maria Krauel
Finance & Operations

Unlock access to complete

Board Members and Advisors
people
Roger Perlmutter
Independent Board Director
people
Krishna Yeshwant
Board Observer
people
Vijay Pande
Board Member
people
Paul Mccracken
Board Member

Unlock access to complete

Funding Insights of Insitro

Insitro has successfully raised a total of $643.21M across 3 strategic funding rounds. The most recent funding activity was a Series C round of $400 million completed in March 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding
  • Total Rounds 3
  • Last Round Series C — $400.0M
  • First Round

    (22 Jul 2019)

  • Investors Count 17
Date Amount Transaction Name Valuation Lead Investors Investors
Mar, 2021 Amount Series C - Insitro Valuation CPP Investments
Mar, 2020 Amount Series B - Insitro Valuation a16z
Jul, 2019 Amount Series A - Insitro Valuation Arch Venture Partners , Foresite Capital
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investors in Insitro

Insitro has secured backing from 17 investors, including institutional and venture fund investors. Prominent investors backing the company include Verily, ARE and WuXi AppTec. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.

All
Venture Fund
Institutional
Investor Description Founded Year Domain Location
Venture capital investments in technology sectors are handled by Andreessen Horowitz.
Founded Year Domain Location
Investing in Life Sciences sectors like Healthcare and Biotechnology.
Founded Year Domain Location
Multi-stage investment firm invests in healthcare and life sciences companies
Founded Year Domain Location
Investor Description Founded Year Domain Location
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
Founded Year Domain Location
Startup ecosystems are ignited through strategic investments by Signite Partners.
Founded Year Domain Location
Venture capital is directed toward companies in multiple sectors.
Founded Year Domain Location
Venture capital is invested in cybersecurity, fintech, and AI startups.
Founded Year Domain Location

Investments & Acquisitions by Insitro

Insitro has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Haystack Sciences. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Acquisitions
Company Name Description Domain Location Founded Year Amount
Proprietary platform employed for small molecule drug discovery.
2016
Company Name Description Domain Location Founded Year Amount
OVO is recognized as a smart digital payment application.
2017
Bionic investment advisor platform
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014

Financial Statements - Insitro

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Insitro Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of Insitro

Insitro operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as BridgeBio, Spark Therapeutics, Alnylam, ATAI and Ultragenyx, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Therapeutics for genetic diseases are developed through targeted interventions.
domain founded_year HQ Location
Gene therapies for rare diseases including retinal dystrophies are developed.
domain founded_year HQ Location
RNA interference-based therapeutics are developed for multiple disorders.
domain founded_year HQ Location
A biopharmaceutical company accelerating innovative mental health treatments.
domain founded_year HQ Location
Therapeutics for rare and ultra-rare metabolic diseases are developed.
Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Frequently Asked Questions about Insitro

When was Insitro founded?

Insitro was founded in 2018 and raised its 1st funding round 1 year after it was founded.

Where is Insitro located?

Insitro is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.

Is Insitro a funded company?

Insitro is a funded company, having raised a total of $643.21M across 3 funding rounds to date. The company's 1st funding round was a Series A of $100M, raised on Jul 22, 2019.

How many employees does Insitro have?

As of Dec 31, 2023, the latest employee count at Insitro is 257.

What does Insitro do?

Insitro was founded in 2018 and is headquartered in San Francisco, United States. An AI-enabled technology platform is utilized by the company to advance drug discovery and development. Focus is placed on infectious diseases such as HIV and hepatitis C, alongside cancer and genetic conditions like cystic fibrosis. Operations center on integrating machine learning with biological data to identify therapeutic targets in the biotechnology sector.

Who are the top competitors of Insitro?

Insitro's top competitors include Spark Therapeutics, BridgeBio and Forge Biologics.

What products or services does Insitro offer?

Insitro offers insitro Platform and Therapeutic Pipeline.

How many acquisitions has Insitro made?

Insitro has made 1 acquisition, including Haystack Sciences.

Who are Insitro's investors?

Insitro has 17 investors. Key investors include Verily, ARE, WuXi AppTec, BlackRock, and Mubadala.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available